Literature DB >> 26472457

Intravascular AAV9 Administration for Delivering RNA Silencing Constructs to the CNS and Periphery.

Brett D Dufour1,2, Jodi L McBride3,4,5.   

Abstract

Viral vector delivery of RNA silencing constructs, when administered into vasculature, typically results in poor central nervous system (CNS) transduction due to the inability of the vector to cross the blood-brain barrier (BBB). However, adeno-associated virus serotype 9 (AAV9) has the ability to cross the BBB and robustly transduce brain parenchyma and peripheral tissues at biologically meaningful levels when injected intravenously. Recent work by our lab has shown that this method can be used to deliver RNA silencing constructs, resulting in significant reductions in gene expression in multiple brain regions and in peripheral tissues. Here, we outline a method for delivery of AAV9 vectors expressing RNA interference (RNAi) constructs that lead to robust simultaneous transduction of mouse peripheral tissues and the CNS following a single injection into the jugular vein. Additionally, we outline methods for necropsy and immunofluorescence to detect AAV9 transduction patterns in the rodent CNS following a vascular delivery.

Entities:  

Keywords:  AAV9, systemic; Gene therapy; Jugular vein; RNAi; Vascular

Mesh:

Year:  2016        PMID: 26472457      PMCID: PMC5519340          DOI: 10.1007/978-1-4939-3112-5_21

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  10 in total

1.  Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.

Authors:  Brett D Dufour; Catherine A Smith; Randall L Clark; Timothy R Walker; Jodi L McBride
Journal:  Mol Ther       Date:  2014-01-06       Impact factor: 11.454

2.  Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS.

Authors:  Kevin D Foust; Desirée L Salazar; Shibi Likhite; Laura Ferraiuolo; Dara Ditsworth; Hristelina Ilieva; Kathrin Meyer; Leah Schmelzer; Lyndsey Braun; Don W Cleveland; Brian K Kaspar
Journal:  Mol Ther       Date:  2013-09-06       Impact factor: 11.454

3.  Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice.

Authors:  Kamal K E Gadalla; Mark E S Bailey; Rosemary C Spike; Paul D Ross; Kenton T Woodard; Sahana Nagabhushan Kalburgi; Lavanya Bachaboina; Jie V Deng; Anne E West; R Jude Samulski; Steven J Gray; Stuart R Cobb
Journal:  Mol Ther       Date:  2012-09-25       Impact factor: 11.454

4.  Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery.

Authors:  Haiyan Fu; Julianne Dirosario; Smruti Killedar; Kimberly Zaraspe; Douglas M McCarty
Journal:  Mol Ther       Date:  2011-03-08       Impact factor: 11.454

5.  Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.

Authors:  Lennart Suckau; Henry Fechner; Elie Chemaly; Stefanie Krohn; Lahouaria Hadri; Jens Kockskämper; Dirk Westermann; Egbert Bisping; Hung Ly; Xiaomin Wang; Yoshiaki Kawase; Jiqiu Chen; Lifan Liang; Isaac Sipo; Roland Vetter; Stefan Weger; Jens Kurreck; Volker Erdmann; Carsten Tschope; Burkert Pieske; Djamel Lebeche; Heinz-Peter Schultheiss; Roger J Hajjar; Wolfgang C Poller
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

6.  Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes.

Authors:  Kevin D Foust; Emily Nurre; Chrystal L Montgomery; Anna Hernandez; Curtis M Chan; Brian K Kaspar
Journal:  Nat Biotechnol       Date:  2008-12-21       Impact factor: 54.908

7.  Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome.

Authors:  Saurabh K Garg; Daniel T Lioy; Hélène Cheval; James C McGann; John M Bissonnette; Matthew J Murtha; Kevin D Foust; Brian K Kaspar; Adrian Bird; Gail Mandel
Journal:  J Neurosci       Date:  2013-08-21       Impact factor: 6.167

8.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection.

Authors:  Carmela Zincarelli; Stephen Soltys; Giuseppe Rengo; Joseph E Rabinowitz
Journal:  Mol Ther       Date:  2008-04-15       Impact factor: 11.454

9.  Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy.

Authors:  Henry Fechner; Isaac Sipo; Dirk Westermann; Sandra Pinkert; Xiaomin Wang; Lennart Suckau; Jens Kurreck; Heinz Zeichhardt; Oliver Müller; Roland Vetter; Volker Erdmann; Carsten Tschope; Wolfgang Poller
Journal:  J Mol Med (Berl)       Date:  2008-06-12       Impact factor: 4.599

10.  Tissue collection for systematic phenotyping in the mouse.

Authors:  Cristina Antal; Marius Teletin; Olivia Wendling; Mounzer Dgheem; Johan Auwerx; Manuel Mark
Journal:  Curr Protoc Mol Biol       Date:  2007-10
  10 in total
  3 in total

1.  Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression.

Authors:  M L Katz; G C Johnson; S B Leach; B G Williamson; J R Coates; R E H Whiting; D P Vansteenkiste; M S Whitney
Journal:  Gene Ther       Date:  2017-02-02       Impact factor: 5.250

2.  RNA interference-based functional knockdown of the voltage-gated potassium channel Kv7.2 in dorsal root ganglion neurons after in vitro and in vivo gene transfer by adeno-associated virus vectors.

Authors:  Markus Valdor; Anke Wagner; Viola Röhrs; Johanna Berg; Henry Fechner; Wolfgang Schröder; Thomas M Tzschentke; Gregor Bahrenberg; Thomas Christoph; Jens Kurreck
Journal:  Mol Pain       Date:  2017-12-06       Impact factor: 3.395

Review 3.  Engineering Nanoparticles for Targeted Delivery of Nucleic Acid Therapeutics in Tumor.

Authors:  Yao Xiao; Kun Shi; Ying Qu; Bingyang Chu; Zhiyong Qian
Journal:  Mol Ther Methods Clin Dev       Date:  2018-09-22       Impact factor: 6.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.